KLRC1 and neoplasm: These results indicate that the therapeutic efficacy of combining NK cells and anti‐NKG2A/Qa‐1b is not restricted to a particular mouse strain or to a tumor cell line, and support the feasible use of donor‐derived allogeneic NK cells.